secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001372514-23-000118
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Q2 net loss $2.6M; ABACUS phase 1b shows KIO-301 proof-of-concept in retinitis pigmentosa
--------------------------------------------------------------------------------

- Net loss $2.6M in Q2 2023 vs $2.4M Q2 2022; cash $8.0M at quarter end.
- Preliminary ABACUS data: KIO-301 safe/tolerable with positive vision impact; topline results expected Q4 2023.
- Sharpened focus on rare retinal diseases; KIO-301 trials to expand to choroideremia and Stargardt's disease.
- Shifted resources from KIO-101 (ocular RA) to KIO-104 (posterior uveitis); seeking partnerships for anterior segment programs.
- Raised $6.3M funding extending runway to May 2024; received $1.2M in R&D tax credits from Australia and Austria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/0001372514-23-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/kprx-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer